142 related articles for article (PubMed ID: 23651025)
1. Genes and beans: pharmacogenomics of renal transplant.
Murray B; Hawes E; Lee RA; Watson R; Roederer MW
Pharmacogenomics; 2013 May; 14(7):783-98. PubMed ID: 23651025
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics and immunosuppressive drugs in solid organ transplantation.
van Gelder T; van Schaik RH; Hesselink DA
Nat Rev Nephrol; 2014 Dec; 10(12):725-31. PubMed ID: 25247332
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients.
Ekbal NJ; Holt DW; Macphee IA
Pharmacogenomics; 2008 May; 9(5):585-96. PubMed ID: 18466104
[TBL] [Abstract][Full Text] [Related]
4. Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation.
Tönshoff B; David-Neto E; Ettenger R; Filler G; van Gelder T; Goebel J; Kuypers DR; Tsai E; Vinks AA; Weber LT; Zimmerhackl LB
Transplant Rev (Orlando); 2011 Apr; 25(2):78-89. PubMed ID: 21454065
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppression in live-related donor renal transplantation.
Iman A; Rao M; Juneja R; Jacob CK
Natl Med J India; 2001; 14(2):75-80. PubMed ID: 11396322
[TBL] [Abstract][Full Text] [Related]
6. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome.
Mourad M; Wallemacq P; De Meyer M; Malaise J; De Pauw L; Eddour DC; Goffin E; Lerut J; Haufroid V
Transplantation; 2008 Apr; 85(7 Suppl):S19-24. PubMed ID: 18401258
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
[TBL] [Abstract][Full Text] [Related]
8. Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?
van Gelder T; Hesselink DA
Clin Pharmacol Ther; 2010 Jun; 87(6):640-1. PubMed ID: 20485320
[TBL] [Abstract][Full Text] [Related]
9. Review: Pharmacodynamic monitoring of immunosuppression in kidney transplantation.
Barraclough KA; Staatz CE; Isbel NM; McTaggart SJ
Nephrology (Carlton); 2010 Aug; 15(5):522-32. PubMed ID: 20649871
[TBL] [Abstract][Full Text] [Related]
10. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?
Nashan B
Transplant Rev (Orlando); 2009 Jan; 23(1):47-52. PubMed ID: 19027616
[TBL] [Abstract][Full Text] [Related]
11. The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients.
Zheng HX; Zeevi A; McCurry K; Schuetz E; Webber S; Ristich J; Zhang J; Iacono A; Dauber J; McDade K; Zaldonis D; Lamba J; Burckart GJ
Transpl Immunol; 2005 Mar; 14(1):37-42. PubMed ID: 15814280
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics: the key to improved drug therapy in transplant patients.
Burckart GJ
Clin Lab Med; 2008 Sep; 28(3):411-22, vi. PubMed ID: 19028260
[TBL] [Abstract][Full Text] [Related]
13. [Cylosporine posological individualization strategies in renal transplant patients].
Porta B; Pérez Ruixo JJ; Jiménez Torres NV; Crespo J
Nefrologia; 2004; 24(5):395-409. PubMed ID: 15648900
[No Abstract] [Full Text] [Related]
14. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.10. Pregnancy in renal transplant recipients.
EBPG Expert Group on Renal Transplantation
Nephrol Dial Transplant; 2002; 17 Suppl 4():50-5. PubMed ID: 12091650
[TBL] [Abstract][Full Text] [Related]
15. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
[TBL] [Abstract][Full Text] [Related]
16. Increased early rejection rate after conversion from tacrolimus in kidney and pancreas transplantation.
Barone GW; Ketel BL; Abul-Ezz SR; Lightfoot ML
JOP; 2002 Mar; 3(2):49-53. PubMed ID: 11884766
[TBL] [Abstract][Full Text] [Related]
17. Practicability of pharmacogenetics in transplantation medicine.
van Gelder T; van Schaik RH; Hesselink DA
Clin Pharmacol Ther; 2014 Mar; 95(3):262-4. PubMed ID: 23995265
[TBL] [Abstract][Full Text] [Related]
18. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
[TBL] [Abstract][Full Text] [Related]
19. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
20. Tacrolimus in pediatric renal transplantation: a review.
Shapiro R
Pediatr Transplant; 1998 Nov; 2(4):270-6. PubMed ID: 10084728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
